Treatment of RA with PFKFB3 inhibitors such as PFK15 or 3PO may reduce pathological phenotypes of RA, but whether this process further aggravates the intrinsic PFKFB3 defect in RA CD T cells, further studies are needed to gain insight into the detailed mechanism of action. The gene discussed is PFKFB3; the disease is rheumatoid arthritis.